EUVIMEDEUVIMED entdecken
Crossref

In Vitro Evaluation of Basiliximab as an Induction Therapy for Xenotransplantation

Hao Feng, Man Zhang, Tianyi Hu, Xiaosheng Tan, Yahui Huang, Song Chen, Fang Zheng, Dengke Pan, Lan Zhu, Gang Chen iD

Xenotransplantation · 2025-11 · 32 (6)

DOI: 10.1111/xen.70101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Xenotransplantation, online erschienen am 05.12.2025. Verfasst von Hao Feng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Transplantation, Heterologous, Antibodies, Monoclonal, Recombinant Fusion Proteins, Graft Rejection. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: National Key Research and Development Program, Special Project of Sichuan Provincial Central Committee guides local science and technology development, Natural Science Foundation of Hubei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Induction therapy is necessary to prevent acute rejection of xenografts. At present, basiliximab is rarely used as an induction therapy agent in solid organ xenotransplantation. In this study, we conducted in vitro experiments to investigate the inhibitory effect of basiliximab on human anti‐porcine xenogeneic immune responses.

Methods

A xenogeneic and allogeneic mixed lymphocyte reaction (MLR) system was established using peripheral blood mononuclear cells (PBMCs) isolated from GTKO/CMAHKO/β4GalNT2KO (triple‐knockout, TKO) pigs or humans as stimulator cells, and another group of human PBMCs as responder cells. Various concentrations of basiliximab were added to the MLR systems as interventions. The inhibitory effects of basiliximab on the proliferation and cytokine production of human T cells were compared.

Results

PBMCs from TKO pigs or humans stimulated significant proliferation of human T cells. Basiliximab inhibited human CD4 + and CD8 + T‐cell proliferation in a typical dose‐dependent manner in both xenogeneic and allogeneic MLR. When the concentration of basiliximab reached 1 µg/mL, the proliferation rates of xenoreactive CD4 + and CD8 + T cells decreased by more than 72%, which was quite similar to the effect in the allogeneic MLR. The inhibitory effects of basiliximab on xenogeneic T‐cell responses were further confirmed by the detection of CD25 expression and supernatant cytokines (IFN‐γ, TNF‐α), and the results were similar to those for allogeneic MLR.

Conclusions

Basiliximab can significantly reduce the xenoreactivity of human lymphocytes against TKO pig cells, and its inhibitory effect is no less than that on allogeneic T cell responses, supporting its potential as induction therapy in xenotransplantation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transplantation, HeterologousAntibodies, MonoclonalRecombinant Fusion ProteinsGraft RejectionImmunosuppressive AgentsHeterograftsBasiliximabAnimalsHumansSwineCell ProliferationLeukocytes, MononuclearLymphocyte Culture Test, MixedT-Lymphocytes

Stichwörter der Autor:innen

basiliximabinduction therapymixed lymphocyte reactiont lymphocytexenotransplantation

Substanzen

BasiliximabAntibodies, MonoclonalRecombinant Fusion ProteinsImmunosuppressive Agents

Autor:innen und Institutionen

  • Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Key Laboratory of Organ Transplantation, Ministry of Education, National Health Commission, Chinese Academy of Medical Sciences, Wuhan, China.
  • Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Chengdu Clonorgan Biotechnology Co., LTD, Chengdu, China.

ORCID-Profile: Gang Chen

Förderung

  • National Key Research and Development Program
  • Special Project of Sichuan Provincial Central Committee guides local science and technology development
  • Natural Science Foundation of Hubei Province
  • National Key Research and Development Program of China

Zitieren

APA

Feng, H., Zhang, M., Hu, T., Tan, X., Huang, Y., Chen, S., Zheng, F., Pan, D., Zhu, L., & Chen, G. (2025). In Vitro Evaluation of Basiliximab as an Induction Therapy for Xenotransplantation. Xenotransplantation, 32(6). https://doi.org/10.1111/xen.70101

Vancouver

Feng H, Zhang M, Hu T, Tan X, Huang Y, Chen S, et al. In Vitro Evaluation of Basiliximab as an Induction Therapy for Xenotransplantation. Xenotransplantation. 2025;32(6). doi:10.1111/xen.70101

BibTeX
@article{Feng2025,
  author = {Feng, Hao and Zhang, Man and Hu, Tianyi and Tan, Xiaosheng and Huang, Yahui and Chen, Song and Zheng, Fang and Pan, Dengke and Zhu, Lan and Chen, Gang},
  title = {In Vitro Evaluation of Basiliximab as an Induction Therapy for Xenotransplantation},
  journal = {Xenotransplantation},
  year = {2025},
  volume = {32},
  number = {6},
  doi = {10.1111/xen.70101}
}
Kostenlos starten →